Polycomb Protein RING1A Limits Differentiation in Myelodysplastic Syndromes
Anna Palau(Josep Carreras Leukaemia Research Institute), Marcus Buschbeck(Josep Carreras Leukaemia Research Institute), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Roberto Malinverni, Anne-Kathrin Garz(TUM Klinikum), Katharina Goetze(TUM Klinikum), Vanesa Valero, J. Diesch, Anabel Zwick
Cited by 0
Related Papers
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients
|Blood|2013|189
Human immunodeficiency virus‐associated plasmablastic lymphoma
|Cancer|2012|178
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma
|Haematologica|2007|123
Influence of highly active anti‐retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome‐related non‐Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone
|British Journal of Haematology|2001|104
Bortezomib plus <scp>EPOCH</scp> is effective as frontline treatment in patients with plasmablastic lymphoma
|British Journal of Haematology|2018|90